New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
15:46 EDTNBYDoctor uses NovaBay product in flesh-eating disease treatment, SFGate says
Dr. John Crew has used NeutroPhase, a NovaBay Pharmaceuticals product approved for cleaning wounds, as part of a new technique he successfully implemented to treat necrotizing fasciitis, which is otherwise known as "flesh-eating disease," while trying to avoid the repeated surgeries typically associated with treatment of the condition, reported SFGate yesterday. Reference Link
News For NBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
09:15 EDTNBYNovaBay reports Q4 EPS (9c), one estimate (7c)
Reports Q4 revenue $385,000, one estimate $60,000. "Avenova sales in February were double January sales, and sales in March are well outpacing those in February. We are making progress on the second component of our plan of introducing innovative eye care products to leverage our salesforce. We expect to introduce a cream version of Avenova for overnight use and are developing additional products that we plan to launch in the coming 12 to 18 months.," said the company. Cash, cash equivalents and short-term investments were $5.4M as of December 31.
March 16, 2015
07:07 EDTNBYNovaBay says 3Q14 Avenova sales about $90,000, Q4 sales about $219,000
07:07 EDTNBYNovaBay sees 1Q15 Avenova sales 'well above' level of Q3, Q4 combined
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use